Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.

Journal of medicinal chemistry - 8 Feb 2024

Tyhonas John S, Arnold Lee D, Cox Jason M, Franovic Aleksandra, Gardiner Elisabeth, Grandinetti Kathryn, Kania Robert, Kanouni Toufike, Lardy Matthew, Li Chun, Martin Eric S, Miller Nichol, Mohan Adithi, Murphy Eric A, Perez Michelle, Soroceanu Liliana, Timple Noel, Uryu Sean, Womble Scott, Kaldor Stephen W

Abstract excerpt

Fibroblast growth factor receptor (FGFR) alterations are present as oncogenic drivers and bypass mechanisms in many forms of cancer. These alterations can include fusions, amplifications, rearrangements, and mutations. Acquired drug resistance to current FGFR inhibitors often results in disease progression and unfavorable outcomes for patients. Genomic profiling of tumors refractory to current FGFR inhibitors in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptor, Fibroblast Growth Factor, Type 3

Source

Identifiers

PMID: 38267212
DOI: 10.1021/acs.jmedchem.3c01819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.PMID 38267212Read ↗

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.Semantic proximity Read ↗

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.Semantic proximity Read ↗

Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations.Semantic proximity Read ↗

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read ↗

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.Semantic proximity Read ↗

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.Semantic proximity Read ↗

Receptor Tyrosine Kinase-Targeted Cancer TherapySemantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.Semantic proximity Read ↗

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.Semantic proximity Read ↗

Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor.Semantic proximity Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.